FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005356987> ?p ?o ?g. }

• W2005356987 endingPage "968" @default.
• W2005356987 startingPage "964" @default.
• W2005356987 abstract "The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity. Patients received capecitabine 2000 mg (4 × 500 mg tablets) twice daily on days 1–14 every 3 weeks. They were reviewed weekly during the first cycle and then three weekly for safety assessment. Eligibility criteria were advanced/metastatic colorectal cancer, ⩽2 prior chemotherapy regimens, ECOG performance status 0–2 and life expectancy >12 weeks. A total of 60 patients were enrolled and 55 were evaluable for efficacy. The median age was 72 years and 63% of patients had a performance status of 1 or 2. Confirmed tumour responses were reported in 15 patients (28%; 95% confidence interval (CI), 15.7–40.3%). The median time to disease progression was 4.9 months and median overall survival was 11.2 months. The median ratio of fixed dose to body surface area (BSA)-calculated dose was 88% (range 65–108%). Significant myelosuppression was not observed. Grade 2/3 treatment-related adverse events were diarrhoea (34%), fatigue (27%), stomatitis (15%) and hand–foot syndrome (22%). Dose reduction due to adverse events was required in 16 patients (29%) and multiple reductions in five patients (9%). There was no grade 3/4 haematological toxicity, any grade 4 adverse events or treatment-related deaths. Patients with higher pretreatment levels of serum folate experienced significantly greater toxicity (P=0.02, CI: 1.0–1.2) during cycle 1 and over the entire treatment period (P=0.04, CI: 1.0–1.3). Pretreatment homocysteine concentrations did not predict for toxicity. In conclusion, fixed-dose capecitabine appears to have similar efficacy and safety compared to the currently recommended dose schedule based on body surface area and simplifies drug administration. A high pretreatment folate may be predictive of increased toxicity from capecitabine." @default.
• W2005356987 created "2016-06-24" @default.
• W2005356987 creator A5007167001 @default.
• W2005356987 creator A5017005208 @default.
• W2005356987 creator A5018463878 @default.
• W2005356987 creator A5056466058 @default.
• W2005356987 creator A5074842604 @default.
• W2005356987 creator A5084855225 @default.
• W2005356987 date "2006-03-21" @default.
• W2005356987 modified "2023-10-07" @default.
• W2005356987 title "A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer" @default.
• W2005356987 cites W126302426 @default.
• W2005356987 cites W144668201 @default.
• W2005356987 cites W1742102714 @default.
• W2005356987 cites W1892571469 @default.
• W2005356987 cites W1910716144 @default.
• W2005356987 cites W1939003096 @default.
• W2005356987 cites W1977691691 @default.
• W2005356987 cites W1986952772 @default.
• W2005356987 cites W1993540056 @default.
• W2005356987 cites W2044970916 @default.
• W2005356987 cites W2071030444 @default.
• W2005356987 cites W2084330540 @default.
• W2005356987 cites W2085262578 @default.
• W2005356987 cites W2097249420 @default.
• W2005356987 cites W2121368761 @default.
• W2005356987 cites W2127500959 @default.
• W2005356987 cites W2128447158 @default.
• W2005356987 cites W2130080188 @default.
• W2005356987 cites W2134617967 @default.
• W2005356987 cites W2138926750 @default.
• W2005356987 cites W2139248078 @default.
• W2005356987 cites W2140626944 @default.
• W2005356987 cites W2162313061 @default.
• W2005356987 cites W2229928428 @default.
• W2005356987 cites W2314927739 @default.
• W2005356987 cites W4244082907 @default.
• W2005356987 doi "https://doi.org/10.1038/sj.bjc.6603049" @default.
• W2005356987 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361225" @default.
• W2005356987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16552436" @default.
• W2005356987 hasPublicationYear "2006" @default.
• W2005356987 type Work @default.
• W2005356987 sameAs 2005356987 @default.
• W2005356987 citedByCount "39" @default.
• W2005356987 countsByYear W20053569872012 @default.
• W2005356987 countsByYear W20053569872013 @default.
• W2005356987 countsByYear W20053569872014 @default.
• W2005356987 countsByYear W20053569872016 @default.
• W2005356987 countsByYear W20053569872017 @default.
• W2005356987 countsByYear W20053569872018 @default.
• W2005356987 countsByYear W20053569872019 @default.
• W2005356987 countsByYear W20053569872020 @default.
• W2005356987 countsByYear W20053569872021 @default.
• W2005356987 countsByYear W20053569872022 @default.
• W2005356987 countsByYear W20053569872023 @default.
• W2005356987 crossrefType "journal-article" @default.
• W2005356987 hasAuthorship W2005356987A5007167001 @default.
• W2005356987 hasAuthorship W2005356987A5017005208 @default.
• W2005356987 hasAuthorship W2005356987A5018463878 @default.
• W2005356987 hasAuthorship W2005356987A5056466058 @default.
• W2005356987 hasAuthorship W2005356987A5074842604 @default.
• W2005356987 hasAuthorship W2005356987A5084855225 @default.
• W2005356987 hasBestOaLocation W20053569871 @default.
• W2005356987 hasConcept C121608353 @default.
• W2005356987 hasConcept C126322002 @default.
• W2005356987 hasConcept C141071460 @default.
• W2005356987 hasConcept C197934379 @default.
• W2005356987 hasConcept C2776694085 @default.
• W2005356987 hasConcept C2776907518 @default.
• W2005356987 hasConcept C2777793932 @default.
• W2005356987 hasConcept C2777909004 @default.
• W2005356987 hasConcept C2779051857 @default.
• W2005356987 hasConcept C29730261 @default.
• W2005356987 hasConcept C526805850 @default.
• W2005356987 hasConcept C71924100 @default.
• W2005356987 hasConcept C90924648 @default.
• W2005356987 hasConceptScore W2005356987C121608353 @default.
• W2005356987 hasConceptScore W2005356987C126322002 @default.
• W2005356987 hasConceptScore W2005356987C141071460 @default.
• W2005356987 hasConceptScore W2005356987C197934379 @default.
• W2005356987 hasConceptScore W2005356987C2776694085 @default.
• W2005356987 hasConceptScore W2005356987C2776907518 @default.
• W2005356987 hasConceptScore W2005356987C2777793932 @default.
• W2005356987 hasConceptScore W2005356987C2777909004 @default.
• W2005356987 hasConceptScore W2005356987C2779051857 @default.
• W2005356987 hasConceptScore W2005356987C29730261 @default.
• W2005356987 hasConceptScore W2005356987C526805850 @default.
• W2005356987 hasConceptScore W2005356987C71924100 @default.
• W2005356987 hasConceptScore W2005356987C90924648 @default.
• W2005356987 hasIssue "7" @default.
• W2005356987 hasLocation W20053569871 @default.
• W2005356987 hasLocation W20053569872 @default.
• W2005356987 hasLocation W20053569873 @default.
• W2005356987 hasLocation W20053569874 @default.
• W2005356987 hasOpenAccess W2005356987 @default.
• W2005356987 hasPrimaryLocation W20053569871 @default.
• W2005356987 hasRelatedWork W191016762 @default.
• W2005356987 hasRelatedWork W2005356987 @default.

• next